BioNTech SE Holds 2025 Annual General Meeting
Ticker: BNTX · Form: 6-K · Filed: May 16, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | May 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: agm, corporate-governance, disclosure
Related Tickers: BNTX
TL;DR
BioNTech held its 2025 AGM on May 16th, releasing presentation and voting results.
AI Summary
On May 16, 2025, BioNTech SE held its Annual General Meeting (AGM) 2025. The company attached the AGM presentation as Exhibit 99.1 and also provided the voting results from the meeting.
Why It Matters
This filing provides shareholders with information presented at the AGM, including voting results, which are key to corporate governance and understanding shareholder sentiment.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of an annual general meeting and its associated materials, posing no immediate new risks.
Key Players & Entities
- BioNTech SE (company) — Registrant
- May 16, 2025 (date) — Date of AGM
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report that BioNTech SE held its Annual General Meeting (AGM) 2025 on May 16, 2025, and to attach the AGM presentation and voting results as exhibits.
When did BioNTech SE hold its 2025 Annual General Meeting?
BioNTech SE held its 2025 Annual General Meeting on May 16, 2025.
What documents are included as part of this Form 6-K?
The documents included are the AGM presentation (Exhibit 99.1) and the voting results from the AGM.
What is the company's principal executive office address?
The company's principal executive office is located at An der Goldgrube 12, D-55131 Mainz, Germany.
Does BioNTech SE file annual reports under Form 20-F or Form 40-F?
BioNTech SE indicates that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 16, 2025 regarding BioNTech SE (BNTX).